Carbamazepine inhibits spontaneous activity in experimental neuromas

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

In eight adult Sprague-Dawley rats the effect of parenteral carbamazepine on spontaneous discharges from saphenous neuromas (7-42 days following nerve section) was tested. Intravenous carbamazepine produced immediate inhibition of spontaneous activity originating in both A- α β and A-δ fibers at doses of 2.51-11.2 (7.9 ± 3.3) mg/kg. In four additional animals, serum levels of carbamazepine were determined following iv administration of the drug. These results indicated that ectopic spontaneous impulse generation from experimental neuromas was inhibited by carbamazepine in the range of serum concentration in which the agent is used to treat trigeminal neuralgia and other painful neuropathies in humans. This implies that the effectiveness of this agent in the treatment of these disorders may result from suppression of peripherally originating ectopic spontaneous activity.

Original languageEnglish (US)
Pages (from-to)249-253
Number of pages5
JournalExperimental Neurology
Volume102
Issue number2
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Neuroma
Carbamazepine
Myelinated Nerve Fibers
Trigeminal Neuralgia
Serum
Sprague Dawley Rats
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neurology

Cite this

Carbamazepine inhibits spontaneous activity in experimental neuromas. / Burchiel, Kim.

In: Experimental Neurology, Vol. 102, No. 2, 1988, p. 249-253.

Research output: Contribution to journalArticle

@article{15a8c442963543d0a6002becaed0f1da,
title = "Carbamazepine inhibits spontaneous activity in experimental neuromas",
abstract = "In eight adult Sprague-Dawley rats the effect of parenteral carbamazepine on spontaneous discharges from saphenous neuromas (7-42 days following nerve section) was tested. Intravenous carbamazepine produced immediate inhibition of spontaneous activity originating in both A- α β and A-δ fibers at doses of 2.51-11.2 (7.9 ± 3.3) mg/kg. In four additional animals, serum levels of carbamazepine were determined following iv administration of the drug. These results indicated that ectopic spontaneous impulse generation from experimental neuromas was inhibited by carbamazepine in the range of serum concentration in which the agent is used to treat trigeminal neuralgia and other painful neuropathies in humans. This implies that the effectiveness of this agent in the treatment of these disorders may result from suppression of peripherally originating ectopic spontaneous activity.",
author = "Kim Burchiel",
year = "1988",
doi = "10.1016/0014-4886(88)90101-X",
language = "English (US)",
volume = "102",
pages = "249--253",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Carbamazepine inhibits spontaneous activity in experimental neuromas

AU - Burchiel, Kim

PY - 1988

Y1 - 1988

N2 - In eight adult Sprague-Dawley rats the effect of parenteral carbamazepine on spontaneous discharges from saphenous neuromas (7-42 days following nerve section) was tested. Intravenous carbamazepine produced immediate inhibition of spontaneous activity originating in both A- α β and A-δ fibers at doses of 2.51-11.2 (7.9 ± 3.3) mg/kg. In four additional animals, serum levels of carbamazepine were determined following iv administration of the drug. These results indicated that ectopic spontaneous impulse generation from experimental neuromas was inhibited by carbamazepine in the range of serum concentration in which the agent is used to treat trigeminal neuralgia and other painful neuropathies in humans. This implies that the effectiveness of this agent in the treatment of these disorders may result from suppression of peripherally originating ectopic spontaneous activity.

AB - In eight adult Sprague-Dawley rats the effect of parenteral carbamazepine on spontaneous discharges from saphenous neuromas (7-42 days following nerve section) was tested. Intravenous carbamazepine produced immediate inhibition of spontaneous activity originating in both A- α β and A-δ fibers at doses of 2.51-11.2 (7.9 ± 3.3) mg/kg. In four additional animals, serum levels of carbamazepine were determined following iv administration of the drug. These results indicated that ectopic spontaneous impulse generation from experimental neuromas was inhibited by carbamazepine in the range of serum concentration in which the agent is used to treat trigeminal neuralgia and other painful neuropathies in humans. This implies that the effectiveness of this agent in the treatment of these disorders may result from suppression of peripherally originating ectopic spontaneous activity.

UR - http://www.scopus.com/inward/record.url?scp=0023696988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023696988&partnerID=8YFLogxK

U2 - 10.1016/0014-4886(88)90101-X

DO - 10.1016/0014-4886(88)90101-X

M3 - Article

C2 - 3181365

AN - SCOPUS:0023696988

VL - 102

SP - 249

EP - 253

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -